Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.61 |
| ▸ | AKT2 | P31751 | 3/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2602375 | 0.93 | AKT1 (0.68) | AKT1AKT2PDE4BAKT3PDE10A | |
| SCHEMBL2602421 | 0.86 | AKT1 (0.68) | AKT1AKT2PDE4BAKT3PDE10A | |
| SCHEMBL13998690 | 0.86 | AKT1 (0.67) | AKT1AKT2PDE4BAKT3PDE10A | |
| SCHEMBL2602412 | 0.81 | AKT1 (0.58) | AKT1AKT2PDE4BAKT3ALDH1A1 | |
| SCHEMBL2602422 | 0.81 | ALDH1A1 (0.65) | AKT1AKT2PDE4BAKT3ALDH1A1 | |
| SCHEMBL15157761 | 0.81 | AKT1 (0.73) | AKT1AKT2PDE4BAKT3PDE10A | |
| SCHEMBL804897 | 0.81 | ALDH1A1 (0.60) | AKT1AKT2PDE4BAKT3ALDH1A1 | |
| SCHEMBL13916708 | 0.80 | ALDH1A1 (0.58) | AKT1AKT2PDE4BAKT3ALDH1A1 | |
| SCHEMBL2602420 | 0.79 | AKT1 (0.56) | AKT1AKT2PDE4BAKT3PDE10A | |
| SCHEMBL2602419 | 0.78 | AKT1 (0.60) | AKT1AKT2PDE4BAKT3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334302-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | AKT1 1576/4885AKT2 1216/4885PDE4B 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.